This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Osiris Corrects Certain Inaccuracies In Media Reports

Osiris Therapeutics, Inc. (NASDAQ: OSIR), issued a statement today correcting certain inaccuracies in media reports following the announcement of its favorable agreement with the United States Food and Drug Administration (FDA) regarding Grafix®.

  • Grafix is and will continue to be available on the market for the treatment of both acute and chronic wounds, including diabetic foot ulcers, despite media reports suggesting otherwise. As part of the agreement Osiris detailed in its October 21 press release, FDA affirmed that Grafix, indicated as a wound cover for the treatment of acute and chronic wounds, is regulated solely as a human cells, tissues, and cellular and tissue-based product (HCT/P) under section 361 of the Public Health Service Act (PHS Act).
  • A Biologics License Application (BLA) is not required for Grafix to remain on the market for the treatment of acute and chronic wounds, despite media reports suggesting otherwise. Osiris has the opportunity to receive approval of Grafix as a licensed biologic under the BLA pathway. This approval, if obtained, would enhance the claims Osiris would be able to make regarding the wound healing properties of Grafix. Osiris believes this would create significant product differentiation in the market place and increase the value for the Grafix brand. Osiris is actively pursuing submission of a BLA.
  • Osiris has never received a “warning letter” from FDA, contrary to media reports stating otherwise. Furthermore, Osiris Biosurgery, including the products mentioned in the FDA letter, has been inspected twice by the FDA without a single finding of deficiency.

It should be noted that Osiris may not be aware of and may not correct all current or future inaccuracies in media reports.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is the leading stem cell company, having developed the world’s first approved stem cell drug, remestemcel-L, for graft versus host disease. Osiris’ products include Grafix® and Ovation® for acute and chronic wounds, Cartiform®, a viable cartilage mesh for cartilage repair and the latest addition to Osiris’ line of products, OvationOS™, a viable bone matrix. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company's technology and commercial interests.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,076.14 -49.98 -0.28%
S&P 500 2,114.33 -6.46 -0.30%
NASDAQ 5,090.5270 -7.4490 -0.15%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs